ViTi, Inc. is currently developing a novel, blood-based immunodiagnostic test for pediatric TB disease. This novel diagnostic is based on previous studies that have shown that an identifiable subset of human blood cells react vigorously to select Mycobacterium tuberculosis (Mtb) proteins when a young child has TB disease. In children infected with Mtb that do not have TB disease, this subset of human blood cells does not demonstrate the same level of reactivity.

Tuberculosis (TB) disease is a leading cause of illness and death in children less than 5 years old worldwide affecting an estimated 4 to 6 million children each year. Contributing to a large number of deaths within this age group is the fact that standard TB diagnostics that work well in the adult population perform poorly for young children.  As a result of this performance gap, current methods for diagnosing TB disease in children cannot effectively distinguish TB disease from other common causes of respiratory illness.